Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
The present invention discloses an antibody which selectively binds SITR1 dependent on its activation status.
The invention discloses a measles virus based oncolytic tumor therapy. The virus encodes antibodies against CTLA-4 or PD-L1 and has proven effectiveness in a in vivo mouse tumor model.
The antibody recognizes the kinase HIPK2 only when phosphorylated at Thr880 and Ser882 and therefore can be used for predicting kinase activity.
The assembly and maintenance of functional nucleoli is essential for cell viability. DKFZ researchers developed anti-sense oligos that target Alu element-containing RNAs, which are essential for intact nucleoli, for cancer cell specific induction of apoptosis.
Combination therapy of wogonin or rocaglamide together with Bcl-2 inhibitors leads to increased efficacy of ABT-263, even in cancer cells which have acquired resistance to ABT-263, and without affecting proliferation of normal T cells and platelets.
Numerous studies have shown that selective inhibition of the MetAP-II subtype halts the growth of endothelial cells in culture, inhibits angiogenesis in animal models, and is a validated strategy for anti-angiogenic cancer therapy. In addition, MetAP-II has also emerged as a promising target for other indications, including malaria, rheumatoid arthritis, pulmonary hypertension, and obesity. So the invention describes the design of the small molecules which was guided by the chemical structure of fumagillin. The substances have drug-like substructures, exist in novel chemical space, and the active enantiomeric series has been identified. In addition data on solubility and in vitro plasma half life time are available.